Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Bonifati C., Graceffa D., Lora V., Maiani E.
Centre for the study and treatment of psoriasis at the Department of Clinical Dermatology, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy
AIM: To describe the clinical characteristics and the systemic therapies given to a cohort of patients attending for the first time our tertiary outpatients psoriasis clinic.
METHODS: Data were extracted from an electronic database where the patients, mostly eligible for systemic therapies, are consecutively recorded. On the basis of skin disease severity the subjects were classified into 3 groups: mild psoriasis (MP; PASI ≤ 5); mild to moderate psoriasis (MMP; PASI >5<10); moderate to severe psoriasis (MSP; PASI > 10).
RESULTS: Of the two hundred and eighty-nine patients studied, 88 (30.4%) presented MP, 91 (31.5%) MMP and 110 (38%) MSP. Of the above cited patients 89 (30.8%) were affected by psoriatic arthritis. Of the 289 patients, 267 (92.3%) were deemed eligible for a systemic treatment. Of the latter, 228 (85.4%) started a systemic treatment as monotherapy. The percentages of the therapies administered were as follows: i) cyclosporine 65 (28.5%); ii) methotrexate 59 (25.8%); iii) etanercept 33 (44%); iv) adalimumab 25 (33.3%); ustekinumab 17 (22.6%), acitretin 29 (12.7%); golimumab 1 (1.3%).
CONCLUSION: Our data show a composite distribution of patients eligible for a systemic therapy and attending for the first time our centre. The traditional drugs were more frequently administered (67.1%) as compared to biological ones (32.9%).